Patents by Inventor Scott Hepford

Scott Hepford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10533990
    Abstract: An individualized intravenous exogenous insulin-based therapy for infusing insulin intravenously to a subject or a patient to improve impaired hepatic glucose processing. The therapy includes treatment sessions involving the assessment of metabolic factors, forming a subject profile, and matching the subject profile to a diabetic treatment model. Using the diabetic treatment model, a quantity and frequency of intravenous insulin bolus, dosage amounts of magnesium, and dosage amounts of potassium can be calculated. The methods that improve impaired hepatic glucose processing in subjects and patients can simultaneously introduce separated insulin bolus from an insulin reservoir, dosage amounts of magnesium, and dosage amounts of potassium. The subject profile can create a weight management protocol that uses a metabolic enhancement, wherein the individualized intravenous exogenous insulin-based therapy produces a subject or a patient with improved cellular ATP functioning.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 14, 2020
    Inventors: Hunter Michael Alan Carr, Scott Hepford, Carol Ann Wilson, Stanley Tories Lewis, Jr.
  • Publication number: 20190086394
    Abstract: An individualized intravenous exogenous insulin-based therapy for infusing insulin intravenously to a subject or a patient to improve impaired hepatic glucose processing. The therapy includes treatment sessions involving the assessment of metabolic factors, forming a subject profile, and matching the subject profile to a diabetic treatment model. Using the diabetic treatment model, a quantity and frequency of intravenous insulin bolus, dosage amounts of magnesium, and dosage amounts of potassium can be calculated. The methods that improve impaired hepatic glucose processing in subjects and patients can simultaneously introduce separated insulin bolus from an insulin reservoir, dosage amounts of magnesium, and dosage amounts of potassium. The subject profile can create a weight management protocol that uses a metabolic enhancement, wherein the individualized intravenous exogenous insulin-based therapy produces a subject or a patient with improved cellular ATP functioning.
    Type: Application
    Filed: September 20, 2017
    Publication date: March 21, 2019
    Inventors: Hunter Michael Alan Carr, Scott Hepford, Carol Ann Wilson, Stanley Tories Lewis, JR.
  • Patent number: 9652595
    Abstract: A kit for individualized intravenous exogenous insulin-based therapy, which includes a portable data storage in communication with client device processor. The data storage can have computer instructions, a database of metabolic factors, a library of weight management protocols, a diabetic treatment model, and a library of care plan templates. The kit for individualized intravenous exogenous insulin-based therapy includes a blood glucose meter, a plurality of intravenous catheters fluidly engageable with a fluid source, and a plurality of metabolic enhancements.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: May 16, 2017
    Assignee: Diabetes Relief LLC
    Inventors: Hunter Michael Alan Carr, Scott Hepford, Carol Ann Wilson